APLS vs. BPMC, ROIV, RVMD, VRNA, BBIO, ELAN, GRFS, TLX, TGTX, and NUVL
Should you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Verona Pharma (VRNA), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Grifols (GRFS), Telix Pharmaceuticals Limited American Depositary Shares (TLX), TG Therapeutics (TGTX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.
Apellis Pharmaceuticals vs. Its Competitors
Blueprint Medicines (NASDAQ:BPMC) and Apellis Pharmaceuticals (NASDAQ:APLS) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, community ranking, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.
In the previous week, Apellis Pharmaceuticals had 3 more articles in the media than Blueprint Medicines. MarketBeat recorded 12 mentions for Apellis Pharmaceuticals and 9 mentions for Blueprint Medicines. Apellis Pharmaceuticals' average media sentiment score of 1.28 beat Blueprint Medicines' score of 0.97 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media.
Blueprint Medicines has higher earnings, but lower revenue than Apellis Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 4.2% of Blueprint Medicines shares are held by insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Blueprint Medicines received 202 more outperform votes than Apellis Pharmaceuticals when rated by MarketBeat users. Likewise, 66.99% of users gave Blueprint Medicines an outperform vote while only 66.29% of users gave Apellis Pharmaceuticals an outperform vote.
Blueprint Medicines currently has a consensus price target of $129.35, indicating a potential upside of 1.09%. Apellis Pharmaceuticals has a consensus price target of $40.05, indicating a potential upside of 112.71%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Apellis Pharmaceuticals is more favorable than Blueprint Medicines.
Blueprint Medicines has a net margin of -13.19% compared to Apellis Pharmaceuticals' net margin of -34.97%. Blueprint Medicines' return on equity of -77.49% beat Apellis Pharmaceuticals' return on equity.
Blueprint Medicines has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.
Summary
Apellis Pharmaceuticals beats Blueprint Medicines on 10 of the 18 factors compared between the two stocks.
Get Apellis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding APLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apellis Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:APLS) was last updated on 6/14/2025 by MarketBeat.com Staff
